Last updated: February 27, 2026
What is the drug associated with NDC 51167-0122?
NDC 51167-0122 refers to Luspatercept-aamt (marketed as Reblozyl), approved by the FDA in November 2019. It is used to treat anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions and anemia in adults with myelodysplastic syndromes (MDS) with ring sideroblasts and minor or no transfusions.
Market Size and Clinical Adoption
Patient Population
- Beta-thalassemia: Estimated at 2,000-3,000 patients in the U.S. (per the Thalassemia Association).
- MDS with ring sideroblasts: Approx. 15,000-20,000 U.S. patients (per Surveillance, Epidemiology, and End Results Program, SEER).
Prescriber and Institutional Adoption
- Initial adoption in hematology centers.
- Growing usage due to expanded label and favorable early clinical outcomes.
- Expert surveys suggest approximately 40-50% of eligible patients in initial years have been prescribed.
Competitive Landscape
- Alternatives include erythropoiesis-stimulating agents and transfusions.
- No direct biosimilars available as of 2023.
- Price sensitivity exists among payers, especially for off-label use.
Pricing Overview
Wholesale Acquisition Cost (WAC)
- Reported WAC: Approximately $15,000 per 1,200 mg dose, administered subcutaneously every three weeks.
- The typical infusion involves 1,200 mg dose per cycle, resulting in an estimated annual treatment cost of $78,000 (assuming 13 cycles/year).
Actual Price and Payer Negotiations
- Net prices are generally lower after rebates and discounts.
- Commercial insurers and Medicare Part D negotiate substantial rebates, reducing out-of-pocket costs.
Cost Compared to Competitors
| Drug |
Typical Annual Cost |
Indication |
| Luspatercept (Reblozyl) |
~$78,000 |
Thalassemia, MDS |
| Erythropoietin-stimulating agents |
$10,000–$40,000 |
Anemia in chronic kidney disease, chemotherapy |
| Transfusion therapy |
Variable, often >$50,000 |
Correction of anemia in various contexts |
Market Projections
Short-term Outlook (2023-2025)
- The U.S. market for Reblozyl is expected to fetch $300-$500 million annually.
- Growth driven by:
- Increasing diagnosis rates.
- Expanded indications.
- Greater prescriber acceptance.
Long-term Outlook (2025-2030)
- Projected to reach $1 billion in U.S. sales.
- Market expansion to Europe and Asia could add another $200-$400 million in combined revenue.
- Competitive pressures and biosimilar entries may impact pricing and market share.
Factors Influencing Price and Market Share
- Payer negotiations.
- Clinical guidelines updates.
- Patient preference shifts toward oral therapies.
- Manufacturer incentives for broader access.
Regulatory and Policy Considerations
- Reimbursement is contingent on formulary placement.
- CMS and private insurers may impose utilization management strategies.
- Price controls in non-U.S. markets could affect global revenue.
- Continued FDA-approved indications may increase market penetration.
Summary
NDC 51167-0122 (Reblozyl) is positioned as a high-cost biologic targeting niche hematological conditions. Its market remains relatively concentrated, with growth influenced by increased disease prevalence, clinical adoption, and payer negotiations. Price projections suggest steady revenue growth through 2030, contingent on broader indications and market expansion.
Key Takeaways
- Estimated 2023 U.S. sales: $300–$500 million.
- Average treatment cost: ~$78,000 annually per patient.
- Long-term sales potential: Up to $1 billion in the U.S., with expanding international markets.
- Market growth driven by increased diagnoses, improved clinician awareness, and label expansions.
- Biosimilar entry is unlikely before 2025 but remains a future risk to market share.
FAQs
1. What patient groups are most likely to be prescribed Reblozyl?
Patients with beta-thalassemia requiring transfusions and those with MDS with ring sideroblasts are primary candidates. Adoption depends on disease severity and prior treatment responses.
2. How does Reblozyl compare pricing-wise with alternatives?
Reblozyl’s annual treatment cost (~$78,000) exceeds erythropoiesis-stimulating agents significantly but is comparable to other biologics used in hematologic indications.
3. Will biosimilars enter the market?
Potential biosimilar development is likely post-patent expiry, expected around 2030, given biologic pathways and patent protections.
4. What factors could influence price reductions?
Negotiated rebates, biosimilar competition, and payer discount programs.
5. What is the outlook for international sales?
Europe and Asia present growth opportunities, with regulatory approvals pending or granted, but pricing and reimbursement policies vary significantly.
References
- FDA. ("Reblozyl" prescribing information). (2021).
- IQVIA. (2023). US Hematology Market Report.
- Medicare Payment Advisory Commission. (2022). Medical and prescription drug spending.
- National Organization for Rare Disorders. (2022). Thalassemia factsheet.
- Surveillance, Epidemiology, and End Results Program. (2021). Cancer statistics.
